ClueP, Korea's First Non-Face-to-Face Dementia Diagnostic Test Content Supplied to University Hospitals

[Asia Economy Reporter Hyunseok Yoo] Medical big data platform company ClueP announced on the 27th that it has signed a supply contract with Yeungnam University Hospital for ‘K-eRBANS,’ the first non-face-to-face dementia diagnosis content in Korea.

‘K-eRBANS,’ developed by ClueP, has the advantage of allowing non-face-to-face testing using tablet PCs, mobile devices, PCs, etc., in separate spaces where the examiner and the examinee are separated.

K-eRBANS was developed based on non-face-to-face technology and digital technology. Not only can the examiner monitor the examinee in real time from a separate space, but all tests are completed within 30 minutes, reducing the testing time by more than one hour compared to the existing paper-based test method (K-RBANS). After the test is completed, the test results are encrypted and sent to the cloud server, and the results can be easily checked through a dedicated platform, which is expected to improve the efficiency of dementia diagnostic tests.

Kim Ki-hwan, CEO of ClueP, said, "K-eRBANS was developed by integrating non-face-to-face digital technology into K-RBANS, the Korean paper version of Pearson’s internationally certified diagnostic tool RBANS." He added, "It has already been applied as a medical platform based on the international clinical data standard consortium (CDISC), and a clinical trial involving 100 people was conducted jointly with the Department of Psychiatry at Yeungnam University Hospital, establishing clinical evidence."

He continued, "With the spread of COVID-19, the non-face-to-face service market is rapidly growing across the medical field. Starting with the supply contract with Yeungnam University Hospital’s screening center, we plan to expand the service not only to domestic university hospitals but also to general hospitals and clinics, public health centers, welfare centers, and elderly day and night care centers."

Meanwhile, ClueP is a leading domestic medical big data platform venture company, recognized externally for its growth potential and technological capabilities, having been selected as a TIPS (Tech Incubator Program for Startup) company led by private investment under the Ministry of SMEs and Startups. In 2019, it successfully hosted the first domestic international clinical trial data consortium ‘CDISC KOREA SUMMIT.’

This content was produced with the assistance of AI translation services.